Screener
Ginkgo Bioworks DNA Reportable Segment — Restructuring Charges
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCostsAndAssetImpairmentCharges.
The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054298
| Line item | Three Months Ended June 30, 2026 | 2025 | Six Months Ended June 30, 2026 | 2025 |
|---|---|---|---|---|
| General and administrative (1) | 11,108 | 15,986 | 23,831 | 35,639 |
| Stock-based compensation (2) | 8,037 | 18,770 | 24,745 | 36,483 |
| Depreciation and amortization | 12,315 | 15,249 | 25,114 | 30,071 |
| Restructuring charges (3) | — | 3,566 | — | 8,032 |
| Carrying cost of excess space (net of sublease income) (4) | 14,233 | 12,413 | 30,074 | 24,088 |
| Merger and acquisition related expense (income) (5) | 1,106 | (3,617) | 1,106 | (4,535) |
| Other (income) expense, net (6) | (1,355) | (4,686) | 3,410 | (2,436) |
| Loss from continuing operations before income taxes | $(57,193) | $(53,477) | $(133,332) | $(136,699) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Ginkgo Bioworks's reportable segment — restructuring charges?
- Ginkgo Bioworks (DNA) reported reportable segment — restructuring charges of $0 in Q2 2026.
- What does reportable segment — restructuring charges mean?
- These are non-recurring costs associated with reorganizing, downsizing, or streamlining operations within a specific business segment. Investors monitor this to assess the impact of strategic pivots and the potential for future cost savings following operational adjustments.
Ask your AI about Ginkgo Bioworks's reportable segment — restructuring charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude